All In Biotech

Drug Trial Radar · NCT01437254

To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer

A Phase I Study of Cyclotron-produced Tc-99m Pertechnetate (CPERT) in Patients With Thyroid Cancer

Last checked: Nov 19, 2026Latest source record: Nov 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Oct 2011

Primary completion

Apr 2012

Study completion Jan 2015

Sponsor

Lead sponsor
AHS Cancer Control AlbertaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Natural Resources, Canada; Edmonton PET Centre
First posted
Sep 20, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The cyclotron production model of Tc-99m pertechnetate (CPERT) has received significant validation in the independent expert review conducted by Natural Resources Canada (NRCan) in the follow up to the Chalk River crisis. The University of Alberta's Edmonton PET Centre and the Edmonton Radiopharmaceutical Centre is a cyclotron / radiopharmacy unit, providing a safe, cost effective, unsubsidized, and reliable supply of radiopharmaceuticals to hospitals and clinics in Edmonton and northern Alberta. A Phase I study is proposed to show safety of CPERT as well as comparability with generator-produced Tc-99m pertechnetate (GPERT) in subjects with well differentiated thyroid carcinoma post-thyroidectomy and prior to planned I-131 Iodide treatment.

Conditions

  • Thyroid Neoplasms

Interventions

  • CPERTDrug

    Single 340 MBq CPERT scan in first 10 subjects

  • GPERTDrug

    Single 340 MBq GPERT scan in up to 20 case-matched controls

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of CPERTTime frame: 7 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.